Northway Biotech Expands CGMP Cell-Based Manufacturing
The Lithuanian CDMO has opened a new facility in Vilnius that can support advanced and personalized therapies, including cell-based applications, therapeutic vaccines, and 3D human tissue technologies.
Northway Biotech — a member of the Lithuanian consortium for cooperation with MIT — has revealed that it is expanding its development and manufacturing capacity significantly with a new 3,500 sq. m. facility. The EUR 61 million (USD 71 million) facility is located in Vilnius, Lithuania, and features up to 20 independent CGMP manufacturing lines.
In addition to expanding the CDMO’s platform across mammalian and microbial biologics, gene therapy, and cell-based technologies, the new facility also provides new development and CGMP manufacturing capacity for advanced and personalized therapies. Operations are set to begin with the first customers already on board and contracts in place.
Through specialized infrastructure and technologies, the facility can accommodate the development and CGMP manufacturing of autologous and allogeneic cell-based therapies, personalized therapeutic vaccines, regenerative medicine applications, and 3D human tissue technologies. Furthermore, segregated manufacturing infrastructure means that multiple cell-based products and processes can be handled in parallel while stringent requirements for product identity, quality, traceability, and contamination control are maintained.
“Fifteen years ago, we did not have a EUR 61 million center — we had people and ambition. Over the years, we have built practical experience, grown our team, and advanced our cell technology capabilities,” said Prof. Vladas Algirdas Bumelis, founder of the Northway Group, in a company press release (1). “Today, we are systematically taking all of this to an entirely new scale. What seemed like the future of medicine 15 years ago is now being created here in Lithuania.”
“This center is about people,” added President of the Republic of Lithuania, Gitanas Nausėda, in the press release (1). “About scientists who will be able to stay in Lithuania and work with technologies that are shaping the future of medicine. About patients for whom personalized medicine is not an abstract concept, but a real treatment option. And about all of us as a country, proving that we can be not only observers, but creators at the global frontier of science.”
“Lithuania is not only a user of advanced technologies, but also a country where they are created and developed,” commented Edvinas Grikšas, Minister of the Economy and Innovation, in the press release (1). “The opening of the BIO CITY center is an important step in strengthening Lithuania’s biomedical ecosystem and our position in the international market. We have a strong foundation for the sector’s continued growth — Lithuania is home to highly qualified professionals in biomedicine, medicine, and science, while growing investment demonstrates international confidence in our potential.”
Reference
Northway Biotech. First in the Baltics: Northway Biotech Opens €61 Million Cell Therapy and Personalized Medicine CDMO in Vilnius. Press Release, Sept. 3, 2026.